67085-13-6

Basic information

• Product Name: Butoconazole
• Synonyms: 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-N-butyl)-1H-imidazole;1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate;67085-14-7 (Nitrate)
• CAS NO: 67085-13-6
• Molecular Formula: C19H17Cl3N2S
• Molecular Weight: 411.77568
• Mol File: 67085-13-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 566.9 °C at 760 mmHg
• Flash Point: 296.7 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 2.76E-12mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: Butoconazole(CAS DataBase Reference)
• NIST Chemistry Reference: Butoconazole(67085-13-6)
• EPA Substance Registry System: Butoconazole(67085-13-6)

Safety Data

• Hazardous Substances Data: 67085-13-6(Hazardous Substances Data)

Usage

General Description

Butoconazole is a broad-spectrum antifungal medication used to treat vaginal yeast infections. It works by inhibiting the growth of fungi and disrupting their cell membranes, leading to their eventual death. Butoconazole is available as a cream and is applied topically to the affected area. It is generally well-tolerated and has few reported side effects, with the most common being mild irritation or burning at the site of application. Butoconazole is considered safe and effective for the treatment of vaginal yeast infections and is available by prescription.

InChI:InChI=1/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2

Upstream product

• 24966-39-0 2,6-dichlorothiophenol 
• 151837-98-8 Methanesulfonic acid (S)-3-(4-chloro-phenyl)-1-imidazol-1-ylmethyl-propyl ester 
• 64872-76-0 butoconazole 
• 151837-97-7 Methanesulfonic acid (R)-3-(4-chloro-phenyl)-1-imidazol-1-ylmethyl-propyl ester 
• 874-72-6 4-chlorobenzylmagnesium chloride 
• 151837-95-5 (2R)-1-(p-toluenesulphonyloxy)-4-(4-chlorophenyl)butan-2-ol 
• 151909-78-3 (2R)-1-<2-hydroxy-4-(4-chlorophenyl)butyl>-1H-imidazole 
• 151837-96-6 (2S)-1-(p-toluenesulphonyloxy)-4-(4-chlorophenyl)butan-2-ol 
• 151909-79-4 (2S)-1-<2-hydroxy-4-(4-chlorophenyl)butyl>-1H-imidazole 
• 67085-11-4 1-[2-hydroxy-4-(4-chlorophenyl)-n-butyl]imidazole 
• 59363-13-2 1-chloro-4-(4-chlorophenyl)-2-butanol 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 67085-12-5 1-[2-chloro-4-(4-chlorophenyl)-n-butyl]imidazole 

Relevant articles and documents

Solid phase extraction procedure coupled with the chiral LC-ESI-MS/MS method for the enantioseparation and determination of butoconazole enantiomers in rat plasma and tissues: application to the enantioselective study on pharmacokinetics and tissue distribution

In the present study, a highly rapid, sensitive and enantioselective method was developed and fully validated for the separation and determination of butoconazole enantiomers in rat plasma and tissues by liquid chromatography-electrospray ionization coupled with tandem mass spectrometry (LC-ESI-MS/MS). The analytes and internal standard (tioconazole) were both extracted from plasma and tissue samples by the solid phase extraction (SPE) procedure with C18 cartridges. Satisfactory enantioseparation was achieved on a Chiralpak IC column by using acetonitrile/10 mM aqueous ammonium acetate (90?:?10, v/v) as a mobile phase. Butoconazole enantiomers and IS were detected in the multiple reaction monitoring (MRM) mode with a positive electrospray ionization source. A comprehensive validation of this method was conducted over the concentration range of 0.5-250 ng mL-1, and good linearity was obtained for each enantiomer with correlation coefficient (R2) greater than 0.991. The mean extraction recoveries were higher than 90.4%, and the relative error was well within the admissible range of -8.0 to 9.1% and the relative standard deviation was less than 11.5%. All the validation data demonstrated that the desirable specificity, carry-over, linearity, sensitivity, accuracy, precision, extraction recovery, matrix effect and stability were attained from the proposed approach. After validation, the established method was successfully applied to the study on stereoselective pharmacokinetics and tissue distribution in female Sprague-Dawley rats after transdermal administration of 10 mg kg-1 2% rac-butoconazole nitrate cream. It should be noted that this is the first report regarding the stereospecific study of butoconazole enantiomers in vivo. This journal is

HPLC method for separating enantiomers of imidazole derivatives - Antifungal compounds

The aim of this study was to test separation possibility of enantiomers of nine active substances belonging to imidazole derivatives: bifonazole, butoconazole, econazole, enilconazole, fenticonazole, isoconazole, miconazole, sertaconazole and tioconazole. The study was performed using HPLC method and the CHIRALCEL OJ column (10 μm; 250 × 4.6 mm), the mobile phase flow rate of 0.8 mL/min and detection at 220 nm. Mobile phases containing hexane and the following modifiers: alcohols (2-propanol, ethanol, methanol) and diethylamine were tested. At first isocratic elution was used but some enantiomers eluted after a long retention time and their peaks were asymmetrical and too wide. Therefore, a gradient elution was developed allowing to obtain satisfactory retention times and other parameters of enentioseparation of the compounds.